SciSparc to Acquire Endoscope Patent Portfolio, Issuing 19.99% Equity for Entry into Multi-Billion Dollar Market

summarizeZusammenfassung

SciSparc Ltd. is making a significant strategic move by acquiring a comprehensive portfolio of patents and intellectual property related to innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. This acquisition, which involves issuing 19.99% of SciSparc's outstanding share capital, positions the company to enter the multi-billion dollar GERD device market. The substantial equity consideration represents significant dilution for existing shareholders, but the company aims for immediate commercialization and revenue generation by replicating a previously successful licensing model in new territories. This transaction could fundamentally alter SciSparc's business focus and growth trajectory.

check_boxSchlusselereignisse

• Strategic Asset Acquisition

  SciSparc will acquire Xylo Technologies' complete portfolio of patents, trademarks, and intellectual property for innovative endoscopic systems, including the MUSE™ system.

• Significant Equity Consideration

  SciSparc will issue shares representing 19.99% of its outstanding share capital to Xylo as consideration, with an option for pre-funded warrants.

• Entry into New Market

  The acquisition positions SciSparc to enter the multi-billion dollar gastroesophageal reflux disease (GERD) device market.

• Commercialization Plans

  SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing, aiming to replicate Xylo's successful licensing model in new high-growth territories.

auto_awesomeAnalyse

SciSparc Ltd. is making a significant strategic move by acquiring a comprehensive portfolio of patents and intellectual property related to innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. This acquisition, which involves issuing 19.99% of SciSparc's outstanding share capital, positions the company to enter the multi-billion dollar GERD device market. The substantial equity consideration represents significant dilution for existing shareholders, but the company aims for immediate commercialization and revenue generation by replicating a previously successful licensing model in new territories. This transaction could fundamentally alter SciSparc's business focus and growth trajectory.